Welcome to our dedicated page for Mainz Biomed N.V. Ordinary Shares news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V. Ordinary Shares stock.
Mainz Biomed N.V. (symbol: MYNZ) is a pioneering company in the field of molecular genetic diagnostics, dedicated to providing patient-friendly testing solutions for life-threatening conditions. With a mission to improve early detection rates and thereby save lives through science, Mainz Biomed develops market-ready products that are both accurate and easy to use.
One of their key innovations is ColoAlert®, a non-invasive, at-home screening test for colorectal cancer (CRC). Utilizing real-time Polymerase Chain Reaction (PCR) to detect molecular-genetic biomarkers in stool samples, ColoAlert® offers high sensitivity and specificity. This test is available in select European countries and is poised for FDA approval in the United States through the ongoing 'ReconAAsense' clinical trial.
Mainz Biomed aims to expand its market reach by fostering partnerships with laboratories and healthcare providers. The company is also committed to advancing the early detection of other cancers, including pancreatic cancer, through products like PancAlert, which is currently in early stages of development.
Recently, Mainz Biomed showcased ColoAlert® at the UDH Congress, emphasizing its role in enhancing comprehensive health strategies. The company reported a 69% year-over-year revenue increase for ColoAlert® and maintained a stable financial condition with a $7.1 million cash balance at year-end.
In collaboration with healthcare professionals, Mainz Biomed continues to contribute to scientific research and knowledge exchange. This commitment was highlighted by their latest clinical studies, ColoFuture and eAArly DETECT, which demonstrated extraordinary statistical significance in CRC and advanced adenoma detection.
For more details, visit Mainz Biomed's official website at www.mainzbiomed.com.
Mainz Biomed will present its largest colorectal cancer screening study to date at the ASCO 2024 Annual Meeting. The study, combining data from ColoFuture and eAArly DETECT studies, includes 690 subjects across 30 clinical sites. The novel screening test, which uses mRNA biomarkers, FIT tests, and an AI algorithm, showed a 92.3% sensitivity for colorectal cancer and 82.3% for advanced precancerous lesions. This innovative, non-invasive approach aims to enhance early detection of colorectal cancer and advanced adenomas, potentially reducing cancer mortality rates globally. The presentation session will be held on June 1, 2024, from 13:30 to 16:30 CDT.
Mainz Biomed unveiled groundbreaking eAArly DETECT study results at Digestive Disease Week (DDW) 2024, achieving a Poster of Distinction award. The study demonstrated 97% sensitivity for colorectal cancer (CRC) and 82% for advanced precancerous lesions, with 100% detection in high-grade dysplasia patients. Conducted across multiple US sites with 254 clinical subjects, the study utilized a multimodal screening test combining Fecal Immunochemical Test (FIT), proprietary mRNA biomarkers, AI, and machine learning. These findings highlight a significant improvement in CRC and advanced adenoma (AA) detection, aligning with previous European ColoFuture study results. Mainz Biomed aims to shift from cancer detection to prevention, potentially reducing CRC mortality rates worldwide.
Mainz Biomed N.V. will present the results of its eAArly DETECT study at Digestive Disease Week in Washington D.C. The study reported a sensitivity for colorectal cancer of 97% and a specificity of 97%, along with a sensitivity for advanced adenoma of 82%. The results indicate promising performance of a multimodal screening test combining various biomarkers with an AI algorithm to improve early detection rates for colorectal cancer and precancerous conditions.
FAQ
What is the current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ)?
What is the market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ)?
What does Mainz Biomed specialize in?
What is ColoAlert®?
Where is ColoAlert® available?
What recent achievements has Mainz Biomed made?
What is the ReconAAsense trial?
What other products does Mainz Biomed have in development?
How does ColoAlert® differ from other CRC screening tests?
What is Mainz Biomed’s mission?
How does Mainz Biomed contribute to the healthcare sector?
Where can I find more information about Mainz Biomed’s investor relations?
